Cathepsin C-IN-5

Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally active Cathepsin C inhibitor with IC 50 s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity In Vitro Cathepsin C-IN-5 (compound SF38) shows inhibition in THP-1 and U937 cells with IC 50 s of 115.4, 70.2 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Cathepsin C-IN-5 (1500 mg/kg) shows no significant weight loss or toxic reaction within 7 days after the administration in ICR mice . Cathepsin C-IN-5 (10 mg/kg for p.o.; 2 mg/kg for i.v.) shows good bioavailability with F=42.07% . Cathepsin C-IN-5 (2, 10, 50 mg/kg; p.o.) shows effective antiinflammatory activity and potential protective effect in an animal model of ALI . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 male mice (acute lung injury (ALI) mice model) Dosage: 2, 10, 50 mg/kg (one hour after administration, received LPS (20 mg/kg)) Administration: P.o. Result: Decreased the levels of proinflammatory cytokines (TNF-a, IL-6, and GM-CSF) and increased the the concentration of the anti-inflammatory cytokine (IL-10) in a dose-dependent manner. Form:Solid IC50& Target:IC 50 : 59.9 nM (Cat C),4.26 µM (Cat L),>5 µM (Cat S),>5 µM (Cat B),>5 µM (Cat K)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet